Metformina + Sitagliptina Disitfor

Metformin Hydrochloride and Sitagliptin, the active ingredients in Metformina + Sitagliptina Disitfor, are a biguanide and a DPP‑4 inhibitor presented as an oral tablet for systemic use. They are indicated for the management of type 2 diabetes mellitus in adults.

GNH USA supplies Metformina + Sitagliptina Disitfor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformina + Sitagliptina is used in the treatment of type 2 diabetes mellitus, acting on glucose metabolism pathways.

- Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose when combined with diet and exercise. - Inadequate control on metformin alone: provides additional glucose‑lowering effect as add‑on therapy. - Combination therapy: simplifies regimen by delivering metformin and sitagliptin in a single tablet.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea. - Headache or dizziness. - Upper respiratory tract infection symptoms. - Mild hypoglycemia, especially when combined with other antidiabetic agents. - Skin rash or pruritus. - Elevated liver enzymes.

Serious or Rare Side Effects: - Lactic acidosis, a rare but life‑threatening condition. - Severe hypoglycemia, particularly with insulin or sulfonylureas. - Acute pancreatitis presenting with abdominal pain. - Anaphylactic reactions or severe skin reactions such as Stevens‑Johnson syndrome. - Significant renal impairment worsening drug clearance. - Hepatic failure with marked transaminase elevation.

Metformina + Sitagliptina should be used with caution in patients with renal or hepatic impairment, as these conditions affect drug clearance and increase risk of lactic acidosis.

- Renal function: assess eGFR before initiation and periodically thereafter. - Hepatic disease: avoid in patients with active liver disease. - Cardiovascular risk: monitor for signs of heart failure. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk. - Concomitant medications: review for drugs that may increase risk of hypoglycemia or affect renal function. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Metformina + Sitagliptina may interact with several medicines that alter its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate lactic acidosis; discontinue metformin before and after use. - Insulin or sulfonylureas: increase risk of severe hypoglycemia. - Alcohol abuse: heightens lactic acidosis risk.

Moderate Interactions (Monitor Closely): - Cimetidine or other renal‑clearance reducing agents: may raise metformin plasma levels. - ACE inhibitors or ARBs: monitor renal function and potassium. - Diuretics: assess for dehydration and renal function changes. - Other antidiabetic agents: adjust dosing to avoid hypoglycemia. - CYP3A4 inhibitors (e.g., ketoconazole): may affect sitagliptin metabolism.